T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients

[News]

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.

More... (https://www.news-medical.net/news/20250116/T-DM1-reduces-long-term-risk-of-death-in-HER2-positive-breast-cancer-patients.aspx)